The Role of Radiotherapy in Stage I , II Intermediate Grade Non-Hodgkin's Lymphoma

I, II기 Intermediate Grade 임파종에서 방사선 치료의 역할

  • Yun Hyong Geun (Department of Therapeutic Radiology, College of Medicine, Seoul National University) ;
  • Kim Il Han (Department of Therapeutic Radiology, College of Medicine, Seoul National University) ;
  • Kim Heung Tae (Department of Internal Medicine, College of Medicine, Seoul National University) ;
  • Ahn Yong Chan (Department of Therapeutic Radiology, College of Medicine, Seoul National University) ;
  • Kim Jae Sung (Department of Therapeutic Radiology, College of Medicine, Seoul National University) ;
  • Ha Sung Whan (Department of Therapeutic Radiology, College of Medicine, Seoul National University) ;
  • Park Charn Il (Department of Therapeutic Radiology, College of Medicine, Seoul National University)
  • 윤형근 (서울대학교 의과대학 치료방사선과학교실) ;
  • 김일한 (서울대학교 의과대학 치료방사선과학교실) ;
  • 김흥태 (서울대학교 의과대학 내과학교실) ;
  • 안용찬 (서울대학교 의과대학 치료방사선과학교실) ;
  • 김재성 (서울대학교 의과대학 치료방사선과학교실) ;
  • 하성환 (서울대학교 의과대학 치료방사선과학교실) ;
  • 박찬일 (서울대학교 의과대학 치료방사선과학교실)
  • Published : 1991.06.01

Abstract

Radiotherapy result of 162 patients with stage I, II intermediate grade non-Hodgkin's Iymphoma was analyzed to clarify the role and limit of radiotherapy. Of 68 initial failures, 38.2% occurred in field and 61.8% occurred out of field. Proportion of in-field and out-of-field failures in stage I was 30.0% and 70.0%, respectively with involved field treatment and was 43.8% and 56.2% with extended field treatment, respectively; in stage ll , was 16.7% and 83.3%, 41.7% and 58.3%, respectively. The disease free suwival rate at S years was 48.1% for all patients and was 50.3% and 40.4% for patients with stage I and II, respectively. The survival was significantly different by stage. Bulky tumors (${\geq}10$ cm) and B symptoms didn't influence prognosis significantly. The 5 year disease free suwival with extended or wide field was better than that with involved field especially in stage I. Overall survival rates for all patients, patients with stage 1, and ll disease were 57.7%, 65.3% and 52.2% , respectively, after survival gain of the salvage chemotherapy was combined. But the overall survival of stage I disease was not better than that of stage II disease. Thus, extended field was required to achieve better disease free survival and relapsed cases might gain with chemotherapy.